title: Ebola Virus Altered Innate and Adaptive Immune Response Signalling Pathways: Implications for Novel Therapeutic Approaches.
abstract: Ebola virus (EBOV) arise attention for their impressive lethality by the poor immune response and high inflammatory reaction in the patients. It causes a severe hemorrhagic fever with case fatality rates of up to 90%. The mechanism underlying this lethal outcome is poorly understood. In 2014, a major outbreak of Ebola virus spread amongst several African countries, including Leone, Sierra, and Guinea. Although infections only occur frequently in Central Africa, but the virus has the potential to spread globally. Presently, there is no vaccine or treatment is available to counteract Ebola virus infections due to poor understanding of its interaction with the immune system. Accumulating evidence indicates that the virus actively alters both innate and adaptive immune responses and triggers harmful inflammatory responses. In the literature, some reports have shown that alteration of immune signaling pathways could be due to the ability of EBOV to interfere with dendritic cells (DCs), which link innate and adaptive immune responses. On the other hand, some reports have demonstrated that EBOV, VP35 proteins act as interferon antagonists. So, how the Ebola virus altered the innate and adaptive immune response signaling pathways is still an open question for the researcher to be explored. Thus, in this review, I try to summarize the mechanisms of the alteration of innate and adaptive immune response signaling pathways by Ebola virus which will be helpful for designing effective drugs or vaccines against this lethal infection. Further, potential targets, current treatment and novel therapeutic approaches have also been discussed.
authors.affiliation: Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology (B.I.T), Mesra, Ranchi-835215, Jharkhand, India. abitmesra@gmail.com.
authors.forename: Anoop
authors.initials: A
authors.lastname: Kumar
mesh_terms: D056704:Adaptive Immunity; D000349:Africa; D000818:Animals; D000998:Antiviral Agents / Q000737:chemistry / Q000627:therapeutic use; D055808:Drug Discovery; D046129:Ebola Vaccines / Q000627:therapeutic use; D029043:Ebolavirus / Q000276:immunology*; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007113:Immunity, Innate; D015398:Signal Transduction
chemical_list: D000998:Antiviral Agents; D046129:Ebola Vaccines